Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.47%
1,067.36
+4.96
+0.47%
—1,062.401,064.141,071.991,061.02——
SIXC
Communications
SIXC
Communications
SIXC
-0.54%
603.48
-3.26
-0.54%
—606.74606.74609.84602.33——
SIXE
Energy
SIXE
Energy
SIXE
+0.54%
1,244.93
+6.72
+0.54%
—1,238.211,236.601,247.741,232.10——
SIXI
Industrials
SIXI
Industrials
SIXI
+0.68%
1,730.38
+11.77
+0.68%
—1,718.611,723.231,741.481,717.47——
SIXM
Financials
SIXM
Financials
SIXM
+0.33%
639.47
+2.10
+0.33%
—637.37638.27642.30638.27——
SIXR
Staples
SIXR
Staples
SIXR
+0.16%
854.95
+1.36
+0.16%
—853.59854.05858.19851.34——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.11%
218.56
+0.23
+0.11%
—218.33218.33219.73217.15——
SIXT
Technology
SIXT
Technology
SIXT
+1.02%
3,631.59
+36.78
+1.02%
—3,594.813,620.103,657.473,615.34——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.80%
915.77
+7.23
+0.80%
—908.54909.50917.35907.07——
SIXV
Health care
SIXV
Health care
SIXV
+1.19%
1,512.81
+17.81
+1.19%
—1,495.001,499.611,517.101,499.61——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.41%
2,408.21
+9.90
+0.41%
—2,398.312,406.822,421.802,404.22——
4547:TYO
Kissei Pharmaceutical Co Ltd
¥4,155.00
+4.66%
(+185.00) 1D
May 22, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4547...
Open
¥3,995
High
¥4,270
Low
¥3,995
Mkt. cap
193.38B
Avg. vol.
120.57K
Volume
338.20K
Dividend
2.89%
Quarterly dividend
¥30
Ex-dividend date
Mar 30, 2026
P/E ratio
12.53
52-wk high
¥5,040
52-wk low
¥3,500
EPS
¥332
Shares outstanding
46.72M
No. of employees
2K
News stories
From sources across the web
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include: Difelikefalin Fostamatinib Linzagolix Mitiglinide Remogliflozin etabonate Silodosin Tranilast In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.78K
FoundedAug 9, 1946
HeadquartersMatsumoto, Nagano, Japan
SectorPharmaceutical industry
Websitekissei.co.jp
Last report
May 11, 2026
Fiscal period
Q4 2026
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
24.77B / 23.82B
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
22.19B
23.64B
26.80B
24.77B
Cost of goods sold
11.11B
12.03B
14.50B
13.95B
Cost of revenue
11.11B
12.03B
14.50B
13.95B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.97B
20.55B
9.15B
10.07B
Operating expense
8.97B
20.55B
9.15B
10.07B
Total operating expenses
20.08B
32.59B
23.65B
24.02B
Operating income
2.11B
-8.95B
3.16B
756.00M
Other non operating income
16.00M
1.00M
10.00M
-10.00M
EBT including unusual items
5.75B
3.66B
4.20B
3.28B
EBT excluding unusual items
2.80B
-8.82B
3.52B
948.00M
Income tax expense
1.23B
305.00M
915.00M
482.00M
Effective tax rate
21.35%
8.33%
21.81%
14.68%
Other operating expenses
-
-
-
-
Net income
4.52B
3.26B
3.23B
2.76B
Net profit margin
20.36%
13.81%
12.05%
11.16%
Earnings per share
-
-
-
-
Interest and investment income
692.00M
212.00M
614.00M
224.00M
Interest expense
-6.00M
-7.00M
-7.00M
-8.00M
Net interest expenses
686.00M
205.00M
607.00M
216.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
3.26B
-7.82B
4.31B
1.92B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer